Characteristics of Exercise‐Induced Intrapulmonary Arteriovenous Fistula in Patients with Unexplained Exertional Dyspnea
Stephanie J. Kelly(Cincinnati Health Department), Yukitaka Shizukuda(University of Cincinnati), Jean Elwing(University of Cincinnati), Shalabh Singhal(Integrated BioTherapeutics (United States))
Cited by 4
Related Papers
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis
|The Lancet Respiratory Medicine|2018|215
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
|Annals of the Rheumatic Diseases|2022|212
Risk of Major Bleeding with Concomitant Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients Receiving Long‐Term Warfarin Therapy
|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2007|93